IP Library Granted Patent US 9,775,841
Granted Patent B2
US 9,775,841 · App. 13/464,587 · Granted Oct 3, 2017

Compounds as modulators of protein kinases

Inventors: Dhanapalan Nagarathnam (La Chaux-de-Fonds, CH); Swaroop Kumar V. S. Vakkalanka (La Chaux-de-Fonds, CH); Meyyappan Muthuppalaniappan (Hyderabad, IN); Srikant Viswanadha (Hyderabad, IN); Govindarajulu Babu (Hyderabad, IN); Prashant Kashinath Bhavar (Hyderabad, IN)
Assignee: RHIZEN PHARMACEUTICALS SA
A61K31/519A61K31/185A61K31/52A61K31/5355A61K31/5377A61K45/06C07D311/22C07D311/36C07D405/06C07D473/18C07D473/34C07D473/40C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,775,841
App. No.
13/464,587
Granted
Oct 3, 2017
Kind
B2
Abstract

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Claims (6)

1. A compound selected from 2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-l-yl) ethyl)-5-fluoro-3 -(3 -fluorophenyl)- 4H-chromen-4-one and pharmaceutically acceptable salts thereof.

2. A compound selected from (+)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-l-yl) ethyl)-5-fluoro-3-(3-fluorophenyl)- 4H-chromen-4-one, and pharmaceutically acceptable salts thereof.

3. A compound selected from (−)-2-(1-(4-amino-3-(3-fluoro- 4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-l-yl) ethyl)-5-fluoro-3-(3-fluorophenyl)- 4H-chromen-4-one, and pharmaceutically acceptable salts thereof.

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.

Assignments (3)
CHANGE OF ADDRESS Recorded Oct 6, 2021
From: RHIZEN PHARMACEUTICALS AG
To: RHIZEN PHARMACEUTICALS AG
Reel/Frame 057836/0286 →
CHANGE OF ADDRESS Recorded Mar 22, 2021
From: RHIZEN PHARMACEUTICALS SA
To: RHIZEN PHARMACEUTICALS SA
Reel/Frame 056775/0375 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2012
From: NAGARATHNAM, DHANAPALAN; VAKKALANKA, SWAROOP KUMAR V.S.; MUTHUPPALANIAPPAN, MEYYAPPAN; VISWANADHA, SRIKANT; BABU, GOVINDARAJULU; BHAVAR, PRASHANT K
To: RHIZEN PHARMACEUTICALS SA
Reel/Frame 028617/0025 →
Priority Claims (2)
IN 1542/CHE/2011 · May 4, 2011 · national
IN 81/CHE/2012 · Jan 9, 2012 · national
Continuity (1)
Related Publication 20120289496A1 · Nov 15, 2012